R3 Stem Cell Receives Trademark Registration for 'Regenerative Trifecta' Protocol Brand Across Its Global Clinic Network

R3 Stem Cell's trademark for "Regenerative Trifecta" formalizes the brand identity of a clinical protocol used across the eighty-clinic, eight-country network.

The trademark registration for Regenerative Trifecta is a milestone in the company’s intellectual property strategy and follows several years of investment in protocol standardization.”

— David Greene, MD, PhD, MBA

SCOTTSDALE, AZ, UNITED STATES, May 7, 2026 /EINPresswire.com/ -- R3 Stem Cell International today announced that the [United States Patent and Trademark Office (USPTO) has issued a registration for Regenerative Trifecta, the brand name the company uses to identify a standardized clinical protocol deployed across its network of approximately 80 affiliated regenerative medicine clinics in eight countries.

The protocol combines umbilical cord-derived mesenchymal stromal cells (UC-MSCs), extracellular vesicles (commonly described as exosomes), and platelet-rich plasma (PRP) administered under the applicable national regulatory framework of each country of operation. As with all trademark registrations, the issuance establishes brand identity rights for the name “Regenerative Trifecta” and does not constitute evaluation, approval, or endorsement of any underlying clinical product or service by any health authority.

As the world's largest provider of regenerative therapies, R3 Stem Cell International's clinics have performed over 28,000 stem cell procedures globally in the past decade. This includes multiple stem cell clinics in Mexico including Tijuana, Puerto Vallarta and Cancun.

Strategic Context

“Standardizing a single named protocol across 80 clinics in eight countries gives our clinicians, supply partners, and the patients they serve a consistent point of reference,” said Dr. David Greene, CEO of R3 Stem Cell International. “The trademark registration is a milestone in the company’s intellectual property strategy and follows several years of investment in protocol standardization, supply-chain quality systems, and harmonized clinical documentation across our network.”

Company President Samantha Brechner added: “Operating at this scale, in jurisdictions with distinct regulatory frameworks, requires a disciplined approach to nomenclature, training, and quality. The Regenerative Trifecta brand is the public face of an internal standard that our clinical, manufacturing, and quality teams have been refining for five years.”

Protocol Composition and Regulatory Status

The Regenerative Trifecta protocol consists of three components, each prepared and administered under the applicable national regulatory authority of the country of treatment:

• Umbilical cord-derived mesenchymal stromal cells (UC-MSCs), sourced from screened donors and processed in facilities operating under the cell-based product regulations of the country of manufacture, such as COFEPRIS in Mexico and equivalent authorities in other jurisdictions of operation.
• Extracellular vesicles, frequently described in the literature and in clinical practice as exosomes, prepared in accordance with the regulatory framework applicable in the jurisdiction of administration.
• Platelet-rich plasma (PRP), prepared autologously at the point of care from the patient's own blood.

These components are not approved by the U.S. Food and Drug Administration for any clinical indication, and R3 Stem Cell is not a manufacturer or distributor of them within the United States. Treatment is provided exclusively at affiliated clinics located in jurisdictions where the relevant components are authorized under the applicable national regulatory regime, and under the management of locally licensed clinicians.

Industry Context

The global regenerative medicine sector continues to develop in parallel across jurisdictions with distinct regulatory frameworks. Multinational clinic networks face an operational challenge of maintaining consistent clinical protocols, supply standards, and patient documentation across borders. Standardized brand identity for a defined protocol is one element of how operators in this sector communicate consistency to clinicians, partners, payers where applicable, and the general medical and scientific community.

Real-World Evidence Initiatives

The company confirmed that IRB approval has been obtained for a global prospective observational registry on safety for regenerative therapies This registry is intended to systematically describe patient safety using validated outcome measures, with independent oversight, pre-specified analysis, and a commitment to publish results regardless of direction.

About R3 Stem Cell International

R3 Stem Cell International is a multinational regenerative medicine network operating approximately eighty clinics in eight countries including Mexico, UAE, Pakistan, stem cell treatment in India, Philippines, South Africa, USA and Turkey. The company’s clinics deliver cell-based and biologic protocols under the management of locally licensed clinicians and under the regulatory authorities applicable in each country of operation. Additional information is available at https://r3stemcell.com.

Forward-Looking Statements and Regulatory Disclaimer

This announcement contains forward-looking statements regarding the company’s intellectual property strategy, planned research initiatives, and clinical operations. Actual outcomes may differ materially from those described. Statements in this release have not been evaluated by the U.S. Food and Drug Administration. The Regenerative Trifecta protocol is not approved by the U.S. Food and Drug Administration and is not intended to diagnose, treat, cure, or prevent any disease in the United States. Information about the protocol is provided to medical, scientific, and trade audiences for purposes of corporate and intellectual property reporting and is not a solicitation of patients or an offer of treatment to consumers in any jurisdiction.

Press and Industry Contact
David Greene, MD, PhD, MBA
R3 Stem Cell International
Email: dgreene@r3stemcell.com
Phone: (844) GET-STEM
Website: https://r3stemcell.com

David Greene, MD, PhD, MBA
R3 Stem Cell International
+ +1 888-988-0515
email us here
Visit us on social media:
Instagram
Facebook
YouTube

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.